In vivoefficacy of meglumine antimoniate-loaded nanoparticles for cutaneous leishmaniasis: a systematic review / Meliana Borilli Pereira, Bruna Gomes Sydor, Karla Gabriela Memare, Thaís Gomes Verzignassi Silveira, Sandra Mara Alessi Aristides, Eduardo Monguilhott Dalmarco, Jorge Juarez Vieira Teixeira, Maria Valdrinez Campana Lonardoni, Izabel Galhardo Demarchi
Background:Nanotechnology is a promising strategy to improve existing antileishmanial agents.Objective:To explore the evidence of encapsulated meglumine antimoniate for cutaneous leishmaniasis treatment in animal models.Materials & methods:The studies were recovered from PubMed, Scopus, EMBASE, LILACS, WoS and Google according to eligibility criteria following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Population, Intervention, Comparison, Outcomes and Study design (PICOS) strategy. Study appraisal was assessed using the Animal Research Reporting ofIn VivoExperiments, SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) and Grading of Recommendations Assessment, Development and Evaluation (GRADE) recommendations.Results:Five studies were included. Liposomes, metallic and polymeric nanoparticles were tested in BALB/c mice againstLeishmania major,L. tropicaorL. amazonensis.Limitations:Few studies were found to meet the eligibility criteria.Conclusion:All formulations had a significant efficacy, similar to the meglumine antimoniate reference treatment concerning the lesion size and parasite burden. The studies had a high and moderate risk of bias, and the confidence in cumulative evidence was considered low. Therefore, we encourage the development of high-quality preclinical studies.Registration:PROSPERO register CRD42020170191. Background: Objective: Materials & methods: In Vivo Results: Leishmania major L. tropica L. amazonensis Limitations: Conclusion: Registration.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2021 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pereira, Meliana Borilli [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Cutaneous leishmaniasis |
|---|
| Umfang: |
1 Online-Ressource (14 p) |
|---|
| doi: |
10.2217/nnm-2021-0119 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011089385 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011089385 | ||
| 003 | DE-627 | ||
| 005 | 20230713210619.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2021-0119 |2 doi | |
| 035 | |a (DE-627)KFL011089385 | ||
| 035 | |a (KFL)prod_FICIBQ_10.2217/nnm-2021-0119 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Pereira, Meliana Borilli |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vivoefficacy of meglumine antimoniate-loaded nanoparticles for cutaneous leishmaniasis: a systematic review |c Meliana Borilli Pereira, Bruna Gomes Sydor, Karla Gabriela Memare, Thaís Gomes Verzignassi Silveira, Sandra Mara Alessi Aristides, Eduardo Monguilhott Dalmarco, Jorge Juarez Vieira Teixeira, Maria Valdrinez Campana Lonardoni, Izabel Galhardo Demarchi |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2021 | |
| 300 | |a 1 Online-Ressource (14 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background:Nanotechnology is a promising strategy to improve existing antileishmanial agents.Objective:To explore the evidence of encapsulated meglumine antimoniate for cutaneous leishmaniasis treatment in animal models.Materials & methods:The studies were recovered from PubMed, Scopus, EMBASE, LILACS, WoS and Google according to eligibility criteria following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Population, Intervention, Comparison, Outcomes and Study design (PICOS) strategy. Study appraisal was assessed using the Animal Research Reporting ofIn VivoExperiments, SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) and Grading of Recommendations Assessment, Development and Evaluation (GRADE) recommendations.Results:Five studies were included. Liposomes, metallic and polymeric nanoparticles were tested in BALB/c mice againstLeishmania major,L. tropicaorL. amazonensis.Limitations:Few studies were found to meet the eligibility criteria.Conclusion:All formulations had a significant efficacy, similar to the meglumine antimoniate reference treatment concerning the lesion size and parasite burden. The studies had a high and moderate risk of bias, and the confidence in cumulative evidence was considered low. Therefore, we encourage the development of high-quality preclinical studies.Registration:PROSPERO register CRD42020170191. Background: Objective: Materials & methods: In Vivo Results: Leishmania major L. tropica L. amazonensis Limitations: Conclusion: Registration | ||
| 653 | |a cutaneous leishmaniasis | ||
| 653 | |a Leishmania | ||
| 653 | |a meglumine antimoniate | ||
| 653 | |a nanoparticles | ||
| 653 | |a nanotechnology | ||
| 700 | 1 | |a Sydor, Bruna Gomes |e verfasserin |4 aut | |
| 700 | 1 | |a Memare, Karla Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Verzignassi Silveira, Thaís Gomes |e verfasserin |4 aut | |
| 700 | 1 | |a Alessi Aristides, Sandra Mara |e verfasserin |4 aut | |
| 700 | 1 | |a Dalmarco, Eduardo Monguilhott |e verfasserin |4 aut | |
| 700 | 1 | |a Vieira Teixeira, Jorge Juarez |e verfasserin |4 aut | |
| 700 | 1 | |a Campana Lonardoni, Maria Valdrinez |e verfasserin |4 aut | |
| 700 | 1 | |a Demarchi, Izabel Galhardo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine |d London : Future Medicine Ltd, 2006 |h Online-Ressource |w (DE-627)KFL000006122 |w (DE-600)2254848-8 |w (DE-576)398100551 |x 1748-6963 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.2217/nnm-2021-0119 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||